<DOC>
	<DOCNO>NCT00254514</DOCNO>
	<brief_summary>This trial conduct Africa , Europe Middle East . This trial investigate efficacy safety three dose level NorditropinÂ® ( growth hormone ) compare placebo treatment tibia fracture . The trial conduct two part : first part , patient evaluate regard efficacy ( fracture healing ) safety short time interval week 24 post-surgery . In second part , long-term safety fracture heal 12 month post-surgery evaluate .</brief_summary>
	<brief_title>Controlled Study Evaluate Efficacy Safety Treatment With Growth Hormone Tibia Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Tibial Fractures</mesh_term>
	<criteria>Primary surgical treatment tibia fracture use intramedullary nailing Closed fracture : Tscherne Type C1 , C2 C3 Open fracture : Gustilo Grade I , II IIIa Open growth plate Xrays Known chronic endocrine metabolic disease include diabetes severe obesity define body mass index ( BMI ) 1 &gt; 32.0 Severe head injury define patient stuporous comatose pupillary enlargement asymmetry Critically ill patient define patient need mechanical ventilation ( except surgical procedure ) circulatory support ( define use inotropic drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>